Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Accuracy and Errors in Hypothesis Testing01:13

Accuracy and Errors in Hypothesis Testing

199
Hypothesis testing is a fundamental statistical tool that begins with the assumption that the null hypothesis H0 is true. During this process, two types of errors can occur: Type I and Type II. A Type I error refers to the incorrect rejection of a true null hypothesis, while a Type II error involves the failure to reject a false null hypothesis.
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
199
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Errors In Hypothesis Tests01:14

Errors In Hypothesis Tests

4.2K
When performing a hypothesis test, there are four possible outcomes depending on the actual truth (or falseness) of the null hypothesis and the decision to reject or not.
4.2K
Hazard Ratio01:12

Hazard Ratio

121
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
121
Bonferroni Test01:10

Bonferroni Test

2.7K
The Bonferroni test is a statistical test named after Carlo Emilio Bonferroni, an Italian mathematician best known for Bonferroni inequalities. This statistical test is a type of multiple comparison test to determine which means are different than the rest. Bonferroni test can minimize the Type 1 error by reducing the significance level alpha, which otherwise increases with sample pairs.
The means of different samples are first paired in all possible combinations.
The null hypothesis of the...
2.7K
Comparing Experimental Results: Student's t-Test01:09

Comparing Experimental Results: Student's t-Test

1.6K
The t-test is a statistical method used to compare the sample mean with a population mean or compare two means from two data sets. The test statistic is calculated from the standard deviation, mean, and number of measurements in the data set at a selected confidence interval and then compared to a table of critical values at this confidence level. If the test statistic is smaller than the critical value, the null hypothesis is accepted. In this case, we state that the difference between the...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing Methods to Assess Treatment Effect Heterogeneity in General Parametric Regression Models.

Statistics in medicine·2026
Same author

Overview and Practical Recommendations on Using Shapley Values for Identifying Predictive Biomarkers via CATE Modeling.

Statistics in medicine·2026
Same author

Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity.

Statistics in medicine·2025
Same author

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors.

Pharmaceutical statistics·2024
Same author

A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis.

Journal of biomedical informatics·2024
Same author

Editorial for the special collection "Towards neutral comparison studies in methodological research".

Biometrical journal. Biometrische Zeitschrift·2024

Related Experiment Video

Updated: Jul 2, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

All that Glitters Is not Gold: Type-I Error Controlled Variable Selection from Clinical Trial Data.

Manuela R Zimmermann1, Mark Baillie1, Matthias Kormaksson1

  • 1Novartis Pharma AG, Basel, Switzerland.

Clinical Pharmacology and Therapeutics
|February 29, 2024
PubMed
Summary
This summary is machine-generated.

The knockoff framework provides reliable variable selection from clinical trial data, controlling false discoveries. A new method enhances efficiency and error control for biomarker discovery, improving research reproducibility.

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

509

Related Experiment Videos

Last Updated: Jul 2, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

509

Area of Science:

  • Biostatistics
  • Clinical Research Methodology
  • Translational Medicine

Background:

  • Clinical trial data offers rich potential for secondary research, including biomarker discovery and prognostic modeling.
  • Exploratory analyses in clinical settings often suffer from high rates of false discoveries (Type I errors) due to multiple comparisons.
  • Existing variable selection methods may not adequately control for these errors, leading to unclear uncertainty estimates.

Purpose of the Study:

  • To review and extend the knockoff framework for robust variable selection in clinical trial data.
  • To introduce a novel knockoff generation method addressing limitations in mixed data settings and clinical development.
  • To improve the reliability and efficiency of identifying prognostic biomarkers and treatment efficacy predictors.

Main Methods:

  • Review of the knockoff framework, a model-agnostic approach for variable selection with guaranteed Type I error control.
  • Development and application of a novel knockoff generation method optimized for clinical data and mixed data types.
  • Simulation studies to evaluate Type I error control, computational efficiency, and biomarker selection performance.
  • Empirical validation using data from clinical trials for C-reactive protein levels in psoriatic arthritis patients.

Main Results:

  • The novel knockoff generation method provides tighter bounds on Type I error control.
  • Significant improvements in computational efficiency (order of magnitude) were achieved in mixed data settings.
  • The extended framework demonstrated comparable performance to existing methods in identifying prognostic biomarkers.
  • Successful application in identifying biomarkers for C-reactive protein levels in psoriatic arthritis patients across four clinical trials.

Conclusions:

  • The enhanced knockoff framework increases accessibility for variable selection from clinical trial data.
  • This approach helps mitigate the replicability crisis by ensuring reliable biomarker discovery.
  • The method reduces unnecessary research, patient burden, and associated costs in clinical development.